Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor.
Increased endocannabinoid tonus by dual-action fatty acid amide hydrolase (FAAH) and substrate selective cyclooxygenase (COX-2) inhibitors is a promising approach for pain-relief. One such compound with this profile is 2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide (Flu-AM1). These ac...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4583449?pdf=render |
| _version_ | 1818995797465759744 |
|---|---|
| author | Sandra Gouveia-Figueira Jessica Karlsson Alessandro Deplano Sanaz Hashemian Mona Svensson Marcus Fredriksson Sundbom Cenzo Congiu Valentina Onnis Christopher J Fowler |
| author_facet | Sandra Gouveia-Figueira Jessica Karlsson Alessandro Deplano Sanaz Hashemian Mona Svensson Marcus Fredriksson Sundbom Cenzo Congiu Valentina Onnis Christopher J Fowler |
| author_sort | Sandra Gouveia-Figueira |
| collection | DOAJ |
| description | Increased endocannabinoid tonus by dual-action fatty acid amide hydrolase (FAAH) and substrate selective cyclooxygenase (COX-2) inhibitors is a promising approach for pain-relief. One such compound with this profile is 2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide (Flu-AM1). These activities are shown by Flu-AM1 racemate, but it is not known whether its two single enantiomers behave differently, as is the case towards COX-2 for the parent flurbiprofen enantiomers. Further, the effects of the compound upon COX-2-derived lipids in intact cells are not known.COX inhibition was determined using an oxygraphic method with arachidonic acid and 2-arachidonoylglycerol (2-AG) as substrates. FAAH was assayed in mouse brain homogenates using anandamide (AEA) as substrate. Lipidomic analysis was conducted in unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Both enantiomers inhibited COX-2 in a substrate-selective and time-dependent manner, with IC50 values in the absence of a preincubation phase of: (R)-Flu-AM1, COX-1 (arachidonic acid) 6 μM; COX-2 (arachidonic acid) 20 μM; COX-2 (2-AG) 1 μM; (S)-Flu-AM1, COX-1 (arachidonic acid) 3 μM; COX-2 (arachidonic acid) 10 μM; COX-2 (2-AG) 0.7 μM. The compounds showed no enantiomeric selectivity in their FAAH inhibitory properties. (R)-Flu-AM1 (10 μM) greatly inhibited the production of prostaglandin D2 and E2 in both unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Levels of 2-AG were not affected either by (R)-Flu-AM1 or by 10 μM flurbiprofen, either alone or in combination with the FAAH inhibitor URB597 (1 μM).Both enantiomers of Flu-AM1 are more potent inhibitors of 2-AG compared to arachidonic acid oxygenation by COX-2. Inhibition of COX in lipopolysaccharide + interferon γ- stimulated RAW 264.7 cells is insufficient to affect 2-AG levels despite the large induction of COX-2 produced by this treatment. |
| first_indexed | 2024-12-20T21:19:33Z |
| format | Article |
| id | doaj.art-a62dbb4ce5a34f169230d3bb37502d5d |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-20T21:19:33Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-a62dbb4ce5a34f169230d3bb37502d5d2022-12-21T19:26:19ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01109e013921210.1371/journal.pone.0139212Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor.Sandra Gouveia-FigueiraJessica KarlssonAlessandro DeplanoSanaz HashemianMona SvenssonMarcus Fredriksson SundbomCenzo CongiuValentina OnnisChristopher J FowlerIncreased endocannabinoid tonus by dual-action fatty acid amide hydrolase (FAAH) and substrate selective cyclooxygenase (COX-2) inhibitors is a promising approach for pain-relief. One such compound with this profile is 2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide (Flu-AM1). These activities are shown by Flu-AM1 racemate, but it is not known whether its two single enantiomers behave differently, as is the case towards COX-2 for the parent flurbiprofen enantiomers. Further, the effects of the compound upon COX-2-derived lipids in intact cells are not known.COX inhibition was determined using an oxygraphic method with arachidonic acid and 2-arachidonoylglycerol (2-AG) as substrates. FAAH was assayed in mouse brain homogenates using anandamide (AEA) as substrate. Lipidomic analysis was conducted in unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Both enantiomers inhibited COX-2 in a substrate-selective and time-dependent manner, with IC50 values in the absence of a preincubation phase of: (R)-Flu-AM1, COX-1 (arachidonic acid) 6 μM; COX-2 (arachidonic acid) 20 μM; COX-2 (2-AG) 1 μM; (S)-Flu-AM1, COX-1 (arachidonic acid) 3 μM; COX-2 (arachidonic acid) 10 μM; COX-2 (2-AG) 0.7 μM. The compounds showed no enantiomeric selectivity in their FAAH inhibitory properties. (R)-Flu-AM1 (10 μM) greatly inhibited the production of prostaglandin D2 and E2 in both unstimulated and lipopolysaccharide + interferon γ- stimulated RAW 264.7 macrophage cells. Levels of 2-AG were not affected either by (R)-Flu-AM1 or by 10 μM flurbiprofen, either alone or in combination with the FAAH inhibitor URB597 (1 μM).Both enantiomers of Flu-AM1 are more potent inhibitors of 2-AG compared to arachidonic acid oxygenation by COX-2. Inhibition of COX in lipopolysaccharide + interferon γ- stimulated RAW 264.7 cells is insufficient to affect 2-AG levels despite the large induction of COX-2 produced by this treatment.http://europepmc.org/articles/PMC4583449?pdf=render |
| spellingShingle | Sandra Gouveia-Figueira Jessica Karlsson Alessandro Deplano Sanaz Hashemian Mona Svensson Marcus Fredriksson Sundbom Cenzo Congiu Valentina Onnis Christopher J Fowler Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor. PLoS ONE |
| title | Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor. |
| title_full | Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor. |
| title_fullStr | Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor. |
| title_full_unstemmed | Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor. |
| title_short | Characterisation of (R)-2-(2-Fluorobiphenyl-4-yl)-N-(3-Methylpyridin-2-yl)Propanamide as a Dual Fatty Acid Amide Hydrolase: Cyclooxygenase Inhibitor. |
| title_sort | characterisation of r 2 2 fluorobiphenyl 4 yl n 3 methylpyridin 2 yl propanamide as a dual fatty acid amide hydrolase cyclooxygenase inhibitor |
| url | http://europepmc.org/articles/PMC4583449?pdf=render |
| work_keys_str_mv | AT sandragouveiafigueira characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT jessicakarlsson characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT alessandrodeplano characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT sanazhashemian characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT monasvensson characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT marcusfredrikssonsundbom characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT cenzocongiu characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT valentinaonnis characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor AT christopherjfowler characterisationofr22fluorobiphenyl4yln3methylpyridin2ylpropanamideasadualfattyacidamidehydrolasecyclooxygenaseinhibitor |